Shares of ELEKTA AB/ADR (OTCMKTS:EKTAY) hit a new 52-week high on Thursday . The company traded as high as $14.76 and last traded at $14.75, with a volume of 1558 shares changing hands. The stock had previously closed at $14.64.
A number of research analysts recently weighed in on EKTAY shares. ValuEngine downgraded ELEKTA AB/ADR from a “hold” rating to a “sell” rating in a research note on Thursday. Zacks Investment Research raised ELEKTA AB/ADR from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research note on Wednesday, October 23rd.
The stock has a 50 day moving average of $13.29 and a two-hundred day moving average of $13.14. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.86 and a current ratio of 1.08. The firm has a market capitalization of $5.60 billion, a P/E ratio of 44.70, a P/E/G ratio of 2.87 and a beta of 0.46.
About ELEKTA AB/ADR (OTCMKTS:EKTAY)
Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.
See Also: Overbought
Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.